Radient Pharmaceuticals Monetizing China-Based Jade Pharmaceutical Division

US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) (AMEX:RPC ) announced today it anticipates prospective purchasers or financiers will complete due diligence for RPC's China-based subsidiary Jade Pharmaceutical, Inc. ("JPI") by the end of May 2010.

RPC expects JPI will be contractually positioned to move forward with the completion of a sale or financing by the end of the third quarter 2010. RPC currently owns approximately 98% of JPI, which as part of RPC's deconsolidation process, is noted as a special asset on RPC's balance sheet and valued at approximately US$20 million as of September 30, 2009.

Published: 12 April 2010
Written by Editor
AMEX   Healthcare   Project Updates   Up on News  
Read more: Radient Pharmaceuticals ( RPC )

Response Genetics, Inc. Reports Full Year 2009 and Fourth Quarter Financial Results

Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009, as well as an update on the Company’s ResponseDX™ sales activities.

“2009 was a very exciting year for Response Genetics as we saw significant growth and acceptance of our ResponseDX™ diagnostic tests. This trend has continued into 2010, with approximately 800 tests sold in March alone,” said Kathleen Danenberg, Response Genetics president and CEO. “We continue to execute on our successful growth strategy; expanding our sales force, strengthening our balance sheet and establishing an international distribution network. For the coming year, we look forward to building on the momentum we have gained to further increase sales of our diagnostic tests and to advance our pipeline of products.”

Published: 01 April 2010
Written by Editor
Nasdaq   Healthcare   Financial Results   Up on News  
Read more: Response Genetics Inc ( RGDX )

TLCVision to Study DED With the TearLab Osmolarity System

OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq: TEAR) (TSX: TLB.TO), announced today that TLCVision Corporation, North America's premier eye care services company, will be incorporating the TearLab(TM) Osmolarity System ("TearLab System") in eight of its U.S. refractive surgery centers to study Dry Eye Disease ("DED") symptoms as they relate to LASIK surgery.

The TearLab System is intended to measure the osmolarity of human tears to aid in the diagnosis of DED in conjunction with other methods of clinical evaluation. Using a novel lab-on-a-chip approach, the TearLab System requires less than 50 nL (nanoliters) of tear fluid and displays quantitative osmolarity results in less than 30 seconds.

Published: 11 March 2010
Written by Editor
Read more: Occulogix Inc ( TEAR )

New studies show DiagnoCure's PCA3 prostate cancer marker can help guide repeat prostate biopsy decisions and predict risk of aggressive cancer

More than 2,400 men tested in largest worldwide studies to date

DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe (NASDAQ: GPRO), was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer. The studies were presented last week at the American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO GU) in San Francisco.

Published: 08 March 2010
Written by Editor
TSX   Healthcare   Project Updates   Up on News  
Read more: DiagnoCure Inc ( CUR )

Affymetrix Reports Fourth Quarter and Fiscal Year 2009 Results

Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the fourth quarter and fiscal year ended December 31, 2009. Total revenue for the fourth quarter was $88.8 million, as compared to total revenue of $78.6 million in the fourth quarter of 2008. In constant currency terms, revenue for the fourth quarter 2009 was positively impacted by $2.6 million as compared to 2008. For the full year 2009, total revenue was $327.1 million as compared to $410.2 million, which included a one-time intellectual property payment of $90 million, for 2008.

For the fourth quarter of 2009, product revenue was $81.0 million, which consisted of consumable revenue of $71.9 million and instrument revenue of $9.1 million. Service revenue was $5.9 million, and royalties and other revenue were $1.9 million. This compares to fourth quarter 2008 product revenue of $66.6 million, service revenue of $8.5 million, and royalties and other revenue of $3.5 million.

Published: 04 February 2010
Written by Editor
Nasdaq   Healthcare   Financial Results   Up on News  
Read more: Affymetrix Inc ( AFFX )
  1. MedMira Inc ( MIR )
  2. Clarient Inc ( CLRT )
  3. Toumaz Holdings ( TMZ.L )
  4. Response Biomedical Corporation ( RBM )
  5. DiagnoCure Inc ( CUR )